First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.82 HKD -1.09% Market Closed
Updated: May 9, 2024

JW (Cayman) Therapeutics Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

JW (Cayman) Therapeutics Co Ltd
Cost of Revenue Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Cost of Revenue
-¥85.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-¥1.9B
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cost of Revenue
-¥1.1B
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-¥992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-¥35.2B
CAGR 3-Years
-61%
CAGR 5-Years
-83%
CAGR 10-Years
-58%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-¥99.9m
CAGR 3-Years
-34%
CAGR 5-Years
-27%
CAGR 10-Years
N/A

See Also

What is JW (Cayman) Therapeutics Co Ltd's Cost of Revenue?
Cost of Revenue
-85.6m CNY

Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Cost of Revenue amounts to -85.6m CNY.

What is JW (Cayman) Therapeutics Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
2%

Over the last year, the Cost of Revenue growth was 2%.